RSS

abiraterone

According to new research from the US, a side-effect of a common prostate cancer drug can, in some men with advanced disease who have a specific genetic variant, actually fuel cancer cells. more

News

Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care more

News

Due to a price drop, the National Institute for Health and Care Excellence (NICE) has agreed that Janssen’s prostate cancer drug, abiraterone is now affordable, going back on its previous decision more

News